Amgen Will Not Pursue Sensipar Indication In Chronic Renal Insufficiency Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III study of secondary hyperparathyroidism drug in patients with chronic renal insufficiency demonstrated incidences of hypocalcemia.